SCHEMBL4083882

SCHEMBL4083882

Nc1cc(-c2ncccn2)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
CASP6 P55212 1/20 0.46
TSHR P16473 3/20 0.45
TP53 P04637 2/20 0.45
PIK3CD O00329 2/20 0.45
PIP5K1C O60331 1/20 0.45
PI4KA P42356 1/20 0.45
PIK3CG P48736 1/20 0.45
PI4KB Q9UBF8 1/20 0.45
ADRB2 P07550 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208442 0.81 TDP1 (0.56) SMN1; SMN2ALDH1A1TSHRTP53PIK3CD
SCHEMBL3027291 0.79 NPC1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL9972528 0.78 TSHR (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL30839800 0.78 TSHR (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL31607615 0.78 TSHR (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL1027167 0.76 RAB9A (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL9566548 0.76 RAB9A (0.75) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL28320775 0.73 AHR (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL1785281 0.73 MKNK1 (0.47) SMN1; SMN2ALDH1A1HPGDMAPTKMO
SCHEMBL24161940 0.72 ALDH1A1 (0.57) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 NPC1 2040/4885RAB9A 1181/4885SMN1; SMN2 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.